Comparative Effectiveness of Cancer Therapies

癌症治疗的比较有效性

基本信息

批准号：
8278731
负责人：
JANE C. WEEKS
金额：
$ 17.28万
依托单位：
DANA-FARBER CANCER INST
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-05-01 至 2017-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8278731
关键词：
Address American Cancer Society Area Cancer Center Cancer Intervention Cancer Patient Cancer-Predisposing Gene Caring Clinical Clinical Trials Colon Carcinoma Commit Dana-Farber Cancer Institute Data Data Collection Data Set Decision Making Development Effectiveness Faculty Funding Grant Health Policy Health Services Intervention Investments Lead Length Literature Malignant Neoplasms Medical Oncologist Medicine Mentors Mentorship Methodology Operative Surgical Procedures Outcome Patients Peer Review Policy Maker Postdoctoral Fellow Public Health Schools Relative (related person)Research Research Personnel Training Training Programs Treatment outcome United States National Institutes of Health Work alternative treatment beneficiary cancer care cancer surgery cancer therapy career career development comparative effectiveness cost effectiveness effectiveness research experience medical schools member minimally invasive next generation novel professor prognostic programs prophylactic routine care skills treatment strategy

项目摘要

DESCRIPTION (provided by applicant): The candidate, Jane Weeks, MD, MSc, is a Professor of Medicine at Harvard Medical School and Dana-Farber Cancer Institute, and Professor of Health Policy and Management at the Harvard School of Public Health. She is a medical oncologist and health services researcher with an established track record as a committed and successful mentor. She is currently providing primary mentorship to four junior faculty members and three post-doctoral trainees, all of whom hold peer-reviewed career development funding from the NIH or American Cancer Society or have applications currently under review. Dr. Weeks is one of the leaders of the Dana-Farber/Harvard Cancer Center Program in Cancer Outcomes Training Program, and is also an active faculty member of 5 other NIH institutional training grants. Dr. Weeks' research sits at the clinical/health policy interface, with a focus on assessing the effectiveness of cancer interventions in real world settings, and identifying barriers to optimal care for all cancer patients. She has helped to define the comparative effectiveness of novel cancer therapies including prophylactic surgery in cancer susceptibility gene carriers and minimally invasive colon cancer surgery, to identify the determinants and outcomes of prognostic understanding in cancer patients, and to assess the cost-effectiveness of expensive new cancer treatments. Although the term "comparative effectiveness research" has gained currency only in the past few years, this is an accurate characterization of her focus throughout her research career. She has initiated and leads a number of large data collection/development efforts to support rigorous observational research on the quality and outcomes of cancer care outside of clinical trials. These projects are not only helping to elucidate gaps and disparities i the quality of cancer care, but also create the opportunity to assess the relative effectiveness of alternative cancer treatment strategies in routine care settings. In this application, she proposes to: 1. Capitalize on past and ongoing investments in developing large data sets on cancer treatment and outcomes to conduct targeted comparative effectiveness research on interventions to treat cancer. 2. Further develop her skills in the methodology of comparative effectiveness research and contribute to the methodologic literature in that area through a new partnership with Dr. Stuart Lipsitz, an experienced statistician with deep expertise in applied and methodologic research on causal inference from observational data. 3. Help to train the next generation of cancer comparative effectiveness researchers. PUBLIC HEALTH RELEVANCE: Rigorous comparative effectiveness research can contribute to addressing important gaps in the evidence supporting optimal decision-making about treatment of patients with cancer. The primary beneficiaries of this work will be cancer patients, since a better understanding of the most effective strategies of care could lead to meaningful improvements in the length and quality of their lives. But policy-makers and taxpayers could benefit as well, if this research reveals that patients are receiving care that is not only ineffective, but also costly.

描述（由申请人提供）：候选人 Jane Weeks，医学博士、理学硕士，是哈佛医学院和达纳法伯癌症研究所的医学教授，也是哈佛公共卫生学院的卫生政策与管理教授。她是一名肿瘤内科医生和卫生服务研究员，作为一名忠诚且成功的导师，有着良好的记录。她目前正在为四名初级教员和三名博士后实习生提供主要指导，他们都持有美国国立卫生研究院或美国癌症协会经过同行评审的职业发展资金，或者目前正在审查申请。 Weeks 博士是丹娜—法伯癌症研究所/哈佛大学癌症中心癌症结果培训计划的领导者之一，也是 NIH 其他 5 个机构培训资助项目的活跃教员。 Weeks 博士的研究涉及临床/健康政策界面，重点是评估现实世界中癌症干预措施的有效性，并确定所有癌症患者获得最佳护理的障碍。她帮助确定了新型癌症疗法的相对有效性，包括癌症易感基因携带者的预防性手术和微创结肠癌手术，确定了癌症患者预后理解的决定因素和结果，并评估了昂贵的新疗法的成本效益。癌症治疗。尽管“比较有效性研究”一词在过去几年才开始流行，但这准确地描述了她整个研究生涯的重点。她发起并领导了许多大型数据收集/开发工作，以支持对临床试验之外的癌症护理质量和结果进行严格的观察研究。这些项目不仅有助于阐明癌症护理质量方面的差距和差异，而且还创造了评估癌症护理相对有效性的机会。常规护理环境中的替代癌症治疗策略。在此申请中，她建议： 1. 利用过去和正在进行的投资开发癌症治疗和结果的大型数据集，对癌症治疗干预措施进行有针对性的比较有效性研究。 2. 通过与 Stuart Lipsitz 博士建立新的合作伙伴关系，进一步发展她在比较有效性研究方法方面的技能，并为该领域的方法论文献做出贡献。Stuart Lipsitz 博士是一位经验丰富的统计学家，在观察数据因果推断的应用和方法学研究方面拥有深厚的专业知识。 3. 帮助培养下一代癌症比较有效性研究人员。公共卫生相关性：严格的比较有效性研究有助于解决支持癌症患者治疗最佳决策的证据中的重要差距。这项工作的主要受益者将是癌症患者，因为更好地了解最有效的护理策略可以使他们的生活长度和质量得到有意义的改善。但如果这项研究表明患者接受的护理不仅无效而且成本高昂，政策制定者和纳税人也可能受益。